Denosumab: a new option in the treatment of bone metastases from urological cancers.

Onco Targets Ther · 2012 · PMC3457675 · PMID 23055747

Europe PMC DOI

hedged sentence

0.1790

closest p · 3.6× alpha

0.1790

boldest claim

The sentences

showed a trendP = 0.179not close (p > 0.1)

7 Although there was no statistical significance compared to placebo, the median overall survival showed a trend toward favoring zoledronic acid (295 days for the 4 mg zoledronic acid group vs 216 days for the placebo group; P = 0.179). 7 These results suggest that zoledronic acid not only decreases SREs, but also improves survival in patients with bone metastatic RCC.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.